Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The EXPLORER-HCM study: mavacamten for obstructive HCM
View through CrossRef
This video summarizes the underlying cause of hypertrophic cardiomyopathy (HCM), common symptoms of HCM, mechanism of action of mavacamten, and key results of the EXPLORER-HCM trial, which compared mavacamten to placebo in patients with obstructive HCM. The results of the EXPLORER-HCM study were recently published in the The Lancet. A plain language summary of the study has subsequently been published in Future Cardiology and helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial.
Title: The EXPLORER-HCM study: mavacamten for obstructive HCM
Description:
This video summarizes the underlying cause of hypertrophic cardiomyopathy (HCM), common symptoms of HCM, mechanism of action of mavacamten, and key results of the EXPLORER-HCM trial, which compared mavacamten to placebo in patients with obstructive HCM.
The results of the EXPLORER-HCM study were recently published in the The Lancet.
A plain language summary of the study has subsequently been published in Future Cardiology and helps patients, their caregivers, patient advocates and healthcare professionals understand the results of the trial.
Related Results
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores t...
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Introduction:
Mavacamten, a cardiac myosin inhibitor, distinguishes from other pharmacological interventions by addressing not only symptomatic treatment but also targe...
Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China
Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China
Aims
To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic car...
Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
Abstract
Background
Hypertrophic cardiomyopathy (HCM) is often accompanied by atrial fibrillation (AF) but data on safety and lo...
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disea...
ASSA13-06-5 Autosomal Recessive Tansmission of MYBPC3 Mutation Resulted in Malignant Phenotpye of Hypertrophic Cardiomyopathy
ASSA13-06-5 Autosomal Recessive Tansmission of MYBPC3 Mutation Resulted in Malignant Phenotpye of Hypertrophic Cardiomyopathy
Background
Hypertrophic cardiomyopathy (HCM) secondary to mutations in genes encoding sarcomere proteins is most commonly inherited as an autosomal dominant trait...
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Aims
Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventric...
Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathy
Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathy
Abstract
Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy, is characterized by phenotypic and genetic heterogeneit...